MDxHealth's 'Blessing in Disguise': A Focused Rebound

After dumping UTI testing, the prostate-cancer diagnostics specialist posts record sequential growth, raises $20M, and leans into AI and Oxford data.

MDXH · Earnings Call · 2026-08-13

From Diversification to Singular Focus

The second quarter of 2026 marked a definitive turning point for MDxHealth. Following the "unanticipated reimbursement developments" that forced the discontinuation of the Resolve UTI test in April, the company executed a rapid strategic pivot. CEO Michael McGarrity framed the quarter as a demonstration of core strength: “We generated a 14% sequential revenue increase or $3.3 million, representing the largest quarter-over-quarter revenue acceleration in our company's history.” — Michael McGarrity, Chief Executive Officer · 2026-08-13 That acceleration was driven by a recovery in the tissue-based business, with a sequential increase of more than 1,400 tests, and the successful transition of all Resolve customers to the prostate cancer menu. The decision to exit UTI testing was not taken lightly. McGarrity had earlier hinted at the silver lining, and in prepared remarks he elaborated: "I believe it would likely end up being a blessing in disguise, one that would manifest as an absolute singular focus on the vertical we have built in the urology market and our prostate cancer franchise, in particular." That focus is now evident in the company's top keywords, which for the first time feature AI initiative and Oxford-related terms (ProMPT, PROTECT) among the hardest movers.

Financial Reset and Capital Raise

The pivot came with a significant financial reset. In Q2, the company completed the wind-down of its Plano, Texas lab, classified Resolve as a discontinued operation, and eliminated a $10.4 million contingent liability to Novitas. As McGarrity stated:

Following the discontinuation of Resolve UTI testing, we completed the cessation of our Plano, Texas lab operations and eliminated the $10.4 million contingent liability to Novitas from our corporate structure as a discontinued operation.
Michael McGarrity, Chief Executive Officer · 2026-08-13

This de-risking was paired with a $20 million registered direct placement with existing shareholders, priced "at the market with no discount or warrant structure," bolstering a pro forma cash position to $39.2 million. The company now expects to return to positive adjusted EBITDA "as we exit 2026," a target that felt distant just months ago when guidance was pulled from $137–140 million to $110–115 million to reflect the discontinued ops. In Q&A, McGarrity reaffirmed the new baseline: “Our current guide at $110 million to $115 million contemplates 20% to 26% growth.” — Michael McGarrity, Chief Executive Officer · 2026-08-13

Data, AI, and the Oxford Relationship

What makes this story compelling beyond the financial reset is the company's forward-looking growth levers. MDxHealth is deepening its partnership with Oxford, having published data from the ProMPT study and progressing the landmark PROTECT trial, which aims to establish active surveillance population as the next big market. The company is also leaning into AI initiative to drive incremental value across its urology and pathology customers. As McGarrity put it: "We continue to advance our AI initiatives, which will deliver meaningful incremental value to both new and existing customers across our urology and pathology stakeholders." This is a clear departure from prior quarters, where the narrative centered on integration and territory realignment. The new focus is on high-growth, data-supported adoption. Notably, the company's tissue based test franchise—Confirm and GPS—is now the entire engine, with the urology market providing a 40%-penetrated opportunity for conversion and share gains. The contrast with prior earnings calls is stark. In February 2026, management was guiding to 28% growth on a larger base; now they are guiding to similar growth on a smaller, cleaner base. The company has consciously traded size for focus, and the market is starting to reward that clarity. As McGarrity said on the call, "This company did not suddenly forget how to operate and execute." In summary, MDxHealth has transformed a reimbursement shock into a strategic reset. With a strengthened balance sheet, a singular prostate-cancer focus, and a pipeline of peer-reviewed data and AI tools, the company is presenting a genuinely new—and more compelling—investment case.